FAAP20 loss

CI-VAR-00004980Explore in graph →CIViC 5065

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
FAAP20 loss	Interventional Radiology Procedure	Predictive	D	Supports Sensitivity Response	2	submitted	EID12212 To evaluate the radiosensitivity of tumours with FAAP20 loss, HeLa, MIA-PaCa-2, and U2OS cells underwent siRNA knockdown of FAAP20 followed by treatment with 0.5 Gy IR. While this dose had minimal eff… (full text at CIViC) PMID 37620397 · Palovcak et al., 2023 · Open in CIViC	civic
FAAP20 loss	PARP Inhibitor AZD2461	Predictive	D	Supports Sensitivity Response	2	submitted	EID12211 To study the impact of FAAP20 loss on sensitivity to PARP inhibitors (PARPi), clonogenic survival assays in HeLa cells and cell proliferation assays in U2OS cells were conducted after FAAP20 knockdown… (full text at CIViC) PMID 37620397 · Palovcak et al., 2023 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.